Motorola Solutions Delivers Unrivalled Versatility for Frontline Workers
27.10.2020 16:00:00 EET | Business Wire | Press release
A global pandemic, ever-increasing volumes of data to manage and greater demand to do more with limited resources - the world has never been more complex for public safety agencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005282/en/
Motorola Solutions' next-generation Terrestrial Trunked Radio (TETRA) device: the MXP600 (Photo: Business Wire)
Siloed systems and devices that don’t talk with each other can add to an already existing complexity. First responders need mission-critical technology that offers an intuitive and smart experience to respond effectively in the “heat of the moment,” as well as flexible tools that enable them to connect seamlessly with a broader ecosystem of technologies.
Motorola Solutions is launching its next-generation Terrestrial Trunked Radio (TETRA) device: the smart and powerful MXP600, to meet the needs of public safety personnel today and well into the future. The lightweight yet highly rugged radio takes the proven capabilities of mission-critical voice communication to new levels and can collaborate with other solutions.
“Frontline professionals will always need their radio in high-stress situations to serve as their lifeline, but they also might require collaboration with other devices that they carry, including smartphones and body worn video cameras, without compromising the security or reliability of their radio voice communications,” said Mark Schmidl, senior vice president at Motorola Solutions.
“Instead of handling multiple devices simultaneously they can activate other devices through the one that feels most natural and intuitive to use in that situation. For example, if a police officer presses the emergency button in a life-threatening situation, the radio will in the future be able to automatically activate the body worn camera, without the officer needing to start the process separately. It's all about simplifying yet elevating key features of mission-critical communications,” explained Katja Millard, senior director devices at Motorola Solutions.
The introduction of the MXP600 will help agencies to flexibly evolve their mission-critical solutions while taking full advantage of the benefits of secure radio voice communications:
- Be clearly heard in the noisiest environments. The MXP600 uses intelligent microphone technology to suppress background noise and has a maximum loudness that is around four times louder than a typical smartphone. When operating in windy conditions, the device automatically uses the loudspeaker as an additional microphone for optimal wind noise mitigation. When multiple radios are in close proximity, the MXP600 automatically eliminates acoustic feedback to allow for effective communication.
- Radically accelerate device management to keep frontline workers in the field. Over-The-Air-Programming (OTAP) makes it possible for radios to be updated on-the-go and within minutes, avoiding the time, logistics and costs involved with traditional radio programming. OTAP is fast, secure and convenient to maximize the productivity of frontline workers and help to keep them in the field.
- Flexible collaboration. Use your radio in the way that suits you best, with a smartphone app for scrolling through talkgroups, sending secure messages and discreet radio communication when you need it. The new M-RadioControl app offers a flexible way for smartphones to work alongside the MXP600. The NFC chip embedded in the MXP600 makes pairing quick and easy, while Bluetooth 5.0 means the wireless connection between radio, smartphone and other devices remains secure.
The MXP600 integrates the technologies emergency services rely upon to focus on their mission to keep the community safe.
Videos
Adaptive Mission-Critical Audio
Designed and Tested for Extreme Conditions
Frontline Safety Today And Tomorrow
Access a media kit with videos and images here.
About Motorola Solutions
Motorola Solutions is a global leader in mission-critical communications and analytics. Our technology platforms in mission-critical communications, command centre software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com.
Follow @MotoSolutions on Twitter
Follow @MotorolaSolutions on Instagram
Follow @MotorolaSolutions on LinkedIn
Like @MotorolaSolutions on Facebook
MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2020 Motorola Solutions, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005282/en/
Contact information
Elvan Lindberg
Motorola Solutions
Mobile: +46 (0)707448893
Elvan.Lindberg@motorolasolutions.com
Susanne Stier
Motorola Solutions
Mobile: +49 (0)172 6161773
Susanne.Stier@motorolasolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom